Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
23 févr. 2017 07h00 HE
|
Actinium Pharmaceuticals
ORLANDO, Fla., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted...
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
21 févr. 2017 07h00 HE
|
Actinium Pharmaceuticals
- Industry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and...
Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations
14 févr. 2017 07h00 HE
|
Actinium Pharmaceuticals
- Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s Iomab-B drug candidate to the bone marrow transplant...
Actinium Pharmaceuticals to Present at Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference
13 févr. 2017 16h15 HE
|
Actinium Pharmaceuticals
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma
13 févr. 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
09 févr. 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma
07 févr. 2017 08h00 HE
|
Actinium Pharmaceuticals
- Phase 1 trial will evaluate Actimab-M in treating patients with multiple myeloma who are unresponsive to currently available therapies - Clinical trial initiated at Texas Oncology - Baylor Charles...
Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms
24 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
- Dr. Berger’s presentation included in session on Immunotherapy and Bispecific Inhibitors in Acute Leukemia - Two day event will be attended by transplant physicians and hematologists...
Actinium Announces Participation in Three Upcoming Hematology Events
20 janv. 2017 07h00 HE
|
Actinium Pharmaceuticals
Representatives from Actinium will attend to promote awareness among attending physicians and health professionals on Iomab-B and the SIERRA trial NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) --...
Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer
18 janv. 2017 08h00 HE
|
Actinium Pharmaceuticals
Dr. Berger brings 20 years of drug development experience highlighted by the FDA approvals of Mylotarg® for acute myeloid leukemia, the only drug approved in AML in several decades, and Tykerb® for...